Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) for April 2024. The report includes an updated presentation about the company's business, which is attached as Exhibit 99.1. This presentation is intended to be considered alongside NeuroSense's SEC filings and other public disclosures. The company, headquartered in Herzliya, Israel, has announced that future versions of its presentations will be available exclusively on its investor relations website. The Form 6-K was signed by CEO Alon Ben-Noon on April 10, 2024.